NeuPath Health (TSXV:NPTH) Piotroski F-Score: 6 (As of Aug. 28, 2026) — 20% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:NPTH NeuPath Health Inc TSXV:NPTH
39 GF Score
Price C$0.55
GF Value C$0.25
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is NeuPath Health Piotroski F-Score?

NeuPath Health TSXV:NPTH 39 Piotroski F-Score is 6 as of Aug. 28, 2026, which is 20% above its 10-year median of 5.00. GuruFocus rates TSXV:NPTH with a GF Score™ of 39/100 and a GF Value™ of C$0.25 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 648 Healthcare Providers & Services companies, NeuPath Health ranks better than 75.31% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

NeuPath Health has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for NeuPath Health's Piotroski F-Score or its related term are showing as below:

TSXV:NPTH' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 6
Current: 6

During the past 7 years, the highest Piotroski F-Score of NeuPath Health was 6. The lowest was 3. And the median was 5.

NeuPath Health  (TSXV:NPTH) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


NeuPath Health Piotroski F-Score Related Terms


NeuPath Health Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for NeuPath Health's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuPath Health Piotroski F-Score Chart

NeuPath Health Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial 4.00 3.00 6.00 5.00 5.00

NeuPath Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 6.00 5.00 5.00 6.00

TSXV:NPTH vs HCA, THC, DVA: Piotroski F-Score Comparison

For the Medical Care Facilities subindustry, NeuPath Health's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuPath Health Piotroski F-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, NeuPath Health's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where NeuPath Health's Piotroski F-Score falls into.


TSXV:NPTH
39GF Score
NeuPath Health Inc TSXV:NPTH
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was -0.153 + -0.409 + 0.313 + 1.592 = C$1.34 Mil.
Cash Flow from Operations was 2.041 + 0.662 + -0.203 + 0.906 = C$3.41 Mil.
Revenue was 22.079 + 22.149 + 21.51 + 23.234 = C$88.97 Mil.
Gross Profit was 4.211 + 4.063 + 3.955 + 4.413 = C$16.64 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(43.825 + 45.928 + 45.09 + 44.827 + 46.588) / 5 = C$45.2516 Mil.
Total Assets at the begining of this year (Jun25) was C$43.83 Mil.
Long-Term Debt & Capital Lease Obligation was C$11.20 Mil.
Total Current Assets was C$14.20 Mil.
Total Current Liabilities was C$11.96 Mil.
Net Income was -0.401 + -0.245 + -0.413 + 0.258 = C$-0.80 Mil.

Revenue was 17.552 + 18.888 + 19.335 + 23.63 = C$79.41 Mil.
Gross Profit was 3.214 + 3.627 + 3.64 + 4.679 = C$15.16 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(41.9 + 41.748 + 41.302 + 42.636 + 43.825) / 5 = C$42.2822 Mil.
Total Assets at the begining of last year (Jun24) was C$41.90 Mil.
Long-Term Debt & Capital Lease Obligation was C$10.75 Mil.
Total Current Assets was C$13.86 Mil.
Total Current Liabilities was C$11.53 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

NeuPath Health's current Net Income (TTM) was 1.34. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

NeuPath Health's current Cash Flow from Operations (TTM) was 3.41. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=1.343/43.825
=0.03064461

ROA (Last Year)=Net Income/Total Assets (Jun24)
=-0.801/41.9
=-0.01911695

NeuPath Health's return on assets of this year was 0.03064461. NeuPath Health's return on assets of last year was -0.01911695. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

NeuPath Health's current Net Income (TTM) was 1.34. NeuPath Health's current Cash Flow from Operations (TTM) was 3.41. ==> 3.41 > 1.34 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=11.203/45.2516
=0.24757136

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=10.746/42.2822
=0.2541495

NeuPath Health's gearing of this year was 0.24757136. NeuPath Health's gearing of last year was 0.2541495. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=14.203/11.958
=1.18774042

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=13.86/11.527
=1.20239438

NeuPath Health's current ratio of this year was 1.18774042. NeuPath Health's current ratio of last year was 1.20239438. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

NeuPath Health's number of shares in issue this year was 60.269. NeuPath Health's number of shares in issue last year was 58.149. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=16.642/88.972
=0.18704761

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=15.16/79.405
=0.19091997

NeuPath Health's gross margin of this year was 0.18704761. NeuPath Health's gross margin of last year was 0.19091997. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=88.972/43.825
=2.03016543

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=79.405/41.9
=1.8951074

NeuPath Health's asset turnover of this year was 2.03016543. NeuPath Health's asset turnover of last year was 1.8951074. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+0+0+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

NeuPath Health has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
NeuPath Health (TSXV:NPTH) has a Piotroski F-Score of 6 as of Aug. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on NeuPath Health and its competitors. This is 20% above median its historical median of 5.00. Over the past decade, NeuPath Health's Piotroski F-Score has ranged from 3.00 to 6.00. According to the industry distribution chart, NeuPath Health ranks #160 out of 648 companies in the Healthcare Providers & Services industry, placing it in the top 24.7%.
Is NeuPath Health's Piotroski F-Score too high?
NeuPath Health's current Piotroski F-Score of 6 is 20% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 6.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. NeuPath Health's value of 6 is 20% above this industry median. Based on the distribution chart, NeuPath Health ranks #160 out of 648 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, NeuPath Health has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuPath Health's Piotroski F-Score compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, NeuPath Health ranks #160 out of 648 companies for Piotroski F-Score. This places NeuPath Health in the top 25% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. NeuPath Health's value of 6 is 20% above this benchmark. Historically, NeuPath Health's own Piotroski F-Score has ranged from 3.00 to 6.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, NeuPath Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 648 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuPath Health's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on NeuPath Health and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuPath Health's current Piotroski F-Score is 6, which is 20% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuPath Health stock overvalued right now?
Based on GuruFocus' analysis, NeuPath Health (TSXV:NPTH) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.25, compared to a current price of C$0.55 — trading 120% above its estimated fair value. The current Piotroski F-Score is 6, which is 20% above median its 10-year median of 5.00 and 20% above the Healthcare Providers & Services industry median of 5.00. NeuPath Health's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For NeuPath Health (TSXV:NPTH), the current Piotroski F-Score is 6 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeuPath Health (TSXV:NPTH) Overvalued in 2026?

Based on GuruFocus' analysis, NeuPath Health stock appears to be overvalued. The current stock price of C$0.55 is trading 120% above its estimated GF Value™ of C$0.25. GuruFocus considers NeuPath Health to be Significantly Overvalued.

Key valuation signals for TSXV:NPTH:

  • Piotroski F-Score: 6 (20% above median its 10-year median of 5.00)
  • GF Value™: C$0.25 vs. price of C$0.55 (120% above fair value)
  • GF Score™: 39/100 with 2 warning signs
  • Industry Position: 20% above the Healthcare Providers & Services median (#160 of 648)

No single metric tells the full story. See the TSXV:NPTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NeuPath Health Business Description

Address 181 Bay Street, Suite 2100, Toronto, ON, CAN, M5J 2T3
NeuPath Health Inc operates an end-to-end, integrated network of healthcare businesses. It utilizes research, data-driven insights, technology, and interdisciplinary care to help restore function for patients impacted by acute and chronic musculoskeletal conditions, including chronic pain, spinal injuries, sports-related injuries, and concussions. It operates an interdisciplinary network of medical clinics in Ontario and Alberta, in addition to an independent medical assessment business with a national network of healthcare providers. Its medical clinics provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal or back injuries, sports-related injuries, and concussions. The company operates in one industry segment: medical services.
39GF Score

Get the complete analysis for TSXV:NPTH

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.55
Price
C$0.25
GF Value